caa a22 4500 475818695 CHVBK 20180406123816.0 cr unu---uuuuu 170329e20001101xx s 000 0 eng 10.1007/s002280000191 doi (NATIONALLICENCE)springer-10.1007/s002280000191 Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers [Elektronische Daten] [Shuichi Tsuruoka, Koh-ichi Sugimoto, Tokie Hayasaka, Tetsuo Saito, Akio Fujimura] Abstract.: Objective: To compare the effect of hemodialysis using two different types of dialyzer membranes, polysulfone (PS), a high-flux membrane, and cuprophane (CP), a conventional membrane, on blood ranitidine concentration. Background: Recent advances in hemodialyzer membranes have improved the removal of small and middle size uremic toxins, while little is known about the change of drug removal by new membranes. Methods: Eight patients with chronic renal failure who received ranitidine (150mg/day) on a chronic basis were included. During the dialysis, blood samples were obtained from both the arterial and venous sides (before and after, respectively) of the dialyzer. Results: Serum concentration of ranitidine decreased more on PS [54±3% (±SEM) reduction after 3h] than on CP (35±4%). The dialyzer clearance of ranitidine on PS membrane (67.2±4.4ml/min/m2) was significantly higher than that on CP (43.1±3.8ml/min/m2, P<0.001). Elimination fraction (EF) of the drug during the dialysis with PS was also significantly higher than that with CP (72±2% versus 44±3%). Apparent half-life of ranitidine during dialysis with PS (2.9±0.4h) was shorter than that with CP (5.1±0.7h). However, the amount of ranitidine removed by a single dialysis with PS membrane was less than 20mg. Conclusion: Ranitidine clearance by hemodialysis is significantly higher with PS than with CP. Although additional dose adjustment may not be needed for ranitidine, the type of dialyzer membrane can affect drug elimination and should be taken into account for consideration of drug removal by hemodialysis. Springer-Verlag, 2000 Ranitidine High-flux membrane Hemodialyzer-clearance nationallicence Tsuruoka Shuichi Department of Clinical Pharmacology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, 329-0498, Kawachi, Tochigi, Japan aut Sugimoto Koh-ichi Department of Clinical Pharmacology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, 329-0498, Kawachi, Tochigi, Japan aut Hayasaka Tokie Moka Hospital, Tochigi, Japan aut Saito Tetsuo Moka Hospital, Tochigi, Japan aut Fujimura Akio Department of Clinical Pharmacology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, 329-0498, Kawachi, Tochigi, Japan aut European Journal of Clinical Pharmacology Springer-Verlag 56/8(2000-11-01), 581-583 0031-6970 56:8<581 2000 56 228 https://doi.org/10.1007/s002280000191 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280000191 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tsuruoka Shuichi Department of Clinical Pharmacology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, 329-0498, Kawachi, Tochigi, Japan aut NATIONALLICENCE 700 1- Sugimoto Koh-ichi Department of Clinical Pharmacology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, 329-0498, Kawachi, Tochigi, Japan aut NATIONALLICENCE 700 1- Hayasaka Tokie Moka Hospital, Tochigi, Japan aut NATIONALLICENCE 700 1- Saito Tetsuo Moka Hospital, Tochigi, Japan aut NATIONALLICENCE 700 1- Fujimura Akio Department of Clinical Pharmacology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, 329-0498, Kawachi, Tochigi, Japan aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 56/8(2000-11-01), 581-583 0031-6970 56:8<581 2000 56 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer